Francesco Azzaroli

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. pmc High doses of ursodeoxycholic acid up-regulate the expression of placental breast cancer resistance protein in patients affected by intrahepatic cholestasis of pregnancy
    Francesco Azzaroli
    Department of Medical and Surgical Sciences, S Orsola Malpighi Hospital, University of Bologna, Italy
    PLoS ONE 8:e64101. 2013
  2. ncbi Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid
    F Azzaroli
    Dipartimento di Medicina Interna e Gastroenterologia, Universita degli Studi di Bologna, Bologna, Italy
    Aliment Pharmacol Ther 26:1139-46. 2007
  3. pmc Pneumatosis cystoides intestinalis
    Francesco Azzaroli
    Department of Clinical Medicine, Division of Gastroenterology, S Orsola Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
    World J Gastroenterol 17:4932-6. 2011
  4. ncbi The pharmacological management of intrahepatic cholestasis of pregnancy
    Francesco Azzaroli
    Department of Clinical Medicine, Gastroenterology Unit, St Orsola Malpighi Hospitali, University of Bologna, Italy
    Curr Clin Pharmacol 6:12-7. 2011
  5. pmc G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence
    Francesca Lodato
    Department of Digestive Diseases and Internal Medicine, University of Bologna, Bologna 40138, Italy
    World J Gastroenterol 15:5449-54. 2009
  6. ncbi Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases
    Davide Festi
    Department of Internal Medicine and Gastroenterology, Policlinico S Orsola Malpighi, Bologna, Italy
    Curr Clin Pharmacol 2:155-77. 2007
  7. ncbi Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial
    M Francesca Jaboli
    Department of Internal Medicine and Gastroenterology, University of Bologna, Italy
    World J Gastroenterol 9:1491-5. 2003
  8. doi High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on
    Marco Montagnani
    Department of Clinical Medicine, Gastroenterology Unit, St Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
    Dig Dis Sci 57:561-7. 2012
  9. ncbi Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis
    Francesco Azzaroli
    Department of Internal Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna
    World J Gastroenterol 10:3099-102. 2004
  10. pmc Proton pump inhibitors in cirrhosis: tradition or evidence based practice?
    Francesca Lodato
    Dipartimento di Medicina Interna e Gastroenterologia, U O di Gastroenterologia, Via Massarenti 9, Bologna 40138, Italy
    World J Gastroenterol 14:2980-5. 2008

Collaborators

Detail Information

Publications32

  1. pmc High doses of ursodeoxycholic acid up-regulate the expression of placental breast cancer resistance protein in patients affected by intrahepatic cholestasis of pregnancy
    Francesco Azzaroli
    Department of Medical and Surgical Sciences, S Orsola Malpighi Hospital, University of Bologna, Italy
    PLoS ONE 8:e64101. 2013
    ..Ursodeoxycholic acid (UDCA) administration in intrahepatic cholestasis of pregnancy (ICP) induces bile acids (BA) efflux from the foetal compartment, but the molecular basis of this transplacental transport is only partially defined...
  2. ncbi Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid
    F Azzaroli
    Dipartimento di Medicina Interna e Gastroenterologia, Universita degli Studi di Bologna, Bologna, Italy
    Aliment Pharmacol Ther 26:1139-46. 2007
    ..The effects of ursodeoxycholic acid on human placental bile acids and bilirubin transporters in intrahepatic cholestasis of pregnancy are still undefined...
  3. pmc Pneumatosis cystoides intestinalis
    Francesco Azzaroli
    Department of Clinical Medicine, Division of Gastroenterology, S Orsola Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
    World J Gastroenterol 17:4932-6. 2011
    ....
  4. ncbi The pharmacological management of intrahepatic cholestasis of pregnancy
    Francesco Azzaroli
    Department of Clinical Medicine, Gastroenterology Unit, St Orsola Malpighi Hospitali, University of Bologna, Italy
    Curr Clin Pharmacol 6:12-7. 2011
    ..The present manuscript will review the current knowledge on the pharmacological treatment of intrahepatic cholestasis of pregnancy...
  5. pmc G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence
    Francesca Lodato
    Department of Digestive Diseases and Internal Medicine, University of Bologna, Bologna 40138, Italy
    World J Gastroenterol 15:5449-54. 2009
    ....
  6. ncbi Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases
    Davide Festi
    Department of Internal Medicine and Gastroenterology, Policlinico S Orsola Malpighi, Bologna, Italy
    Curr Clin Pharmacol 2:155-77. 2007
    ..The future availability of UDCA derivatives will possibly enhance the chances to effectively treat chronic cholestatic diseases...
  7. ncbi Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial
    M Francesca Jaboli
    Department of Internal Medicine and Gastroenterology, University of Bologna, Italy
    World J Gastroenterol 9:1491-5. 2003
    ..To investigate the safety and efficacy of long-term combination therapy with alpha interferon and lamivudine in non-responsive patients with anti-HBe-positive chronic hepatitis B...
  8. doi High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on
    Marco Montagnani
    Department of Clinical Medicine, Gastroenterology Unit, St Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
    Dig Dis Sci 57:561-7. 2012
    ....
  9. ncbi Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis
    Francesco Azzaroli
    Department of Internal Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna
    World J Gastroenterol 10:3099-102. 2004
    ..Data on the preventive effect of IFN plus ribavirin treatment are lacking...
  10. pmc Proton pump inhibitors in cirrhosis: tradition or evidence based practice?
    Francesca Lodato
    Dipartimento di Medicina Interna e Gastroenterologia, U O di Gastroenterologia, Via Massarenti 9, Bologna 40138, Italy
    World J Gastroenterol 14:2980-5. 2008
    ..In conclusion, the use of this class of drugs seems more habit related than evidence-based eventually leading to an increase in health costs...
  11. ncbi Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations
    Francesca Lodato
    Dipartimento di Medicina Interna e Gastroenterologia, UO di Gastroenterologia, Via Massarenti 9, Bologna 40138, Italy
    World J Gastroenterol 12:7239-49. 2006
    ..Thus the real contribution of medical treatment to HCC prevention in patients with chronic viral hepatitis is small. Great efforts are needed to identify more effective medical measures for primary and secondary prevention of HCC...
  12. pmc Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation
    Mariarosa Tamè
    Mariarosa Tamè, Federica Buonfiglioli, Andrea Lisotti, Paolo Cecinato, Antonio Colecchia, Francesco Azzaroli, Rosario Arena, Claudio Calvanese, Chiara Quarneti, Giorgio Ballardini, Giuseppe Mazzella, Department of Digestive Diseases and Internal Medicine, S Orsola Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
    World J Gastroenterol 19:5278-85. 2013
    ..To evaluate the effect of long-term treatment with leukocyte natural α-interferon (ln-α-IFN) plus ribavirin (RBV)...
  13. doi Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience
    Francesca Lodato
    Department of Digestive Diseases and Internal Medicine, S Orsola Malpighi University Hospital, Bologna, Italy
    Scand J Gastroenterol 47:1494-500. 2012
    ..Different models have been proposed for the prediction of survival after TIPS. The aim of this study was to evaluate the predictive factors associated with patients' survival after TIPS placement for refractory ascites...
  14. ncbi Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence
    Francesca Lodato
    Dipartimento di Medicina Interna e Gastroenterologia, U O di Gastroenterologia, Via Massarenti 9, Bologna 40138, Italy
    World J Gastroenterol 12:4253-5. 2006
    ....
  15. ncbi Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy
    Carlo Fabbri
    Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
    World J Gastroenterol 9:1487-90. 2003
    ..To explore the prevalence of autoimmune gastritis in chronic hepatitis C virus (HCV) patients and the influence of alpha-interferon (IFN) treatment on autoimmune gastritis...
  16. ncbi A new model for portal protein profile analysis in course of ileal intraluminal bile acid infusion using an in situ perfused rat intestine
    Marco Montagnani
    Dipartimento di Medicina Clinica, Centro di Ricerca Biomedica Applicata Policlinico S Orsola, Universita di Bologna, Bologna, Italy
    Med Chem 7:257-64. 2011
    ..Since FGF15 was not recovered we suggest the possibilities that this protein is produced in very little amounts, poorly transferred outside the cell, or that it is extremely unstable and rapidly degraded...
  17. ncbi Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: an emerging fungal agent
    Francesca Lodato
    Department of Internal Medicine and Gastroenterology, Sant Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Liver Transpl 12:1711-4. 2006
    ..They may cause both localized and disseminated infection. In conclusion, Fusarium spp. etiology should be considered in the context of infectious diseases following liver transplantation...
  18. doi Adverse effects of proton pump inhibitors
    Francesca Lodato
    Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
    Best Pract Res Clin Gastroenterol 24:193-201. 2010
    ..In fact, in clinical practise, PPI are often prescribed in patients without a specific acid related disease and continued long term based on their safety profile. This review focus on the main adverse events related to long term PPI use...
  19. pmc ESWL for difficult bile duct stones: a 15-year single centre experience
    Rosangela Muratori
    Department of Digestive Diseases and Internal Medicine, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    World J Gastroenterol 16:4159-63. 2010
    ..To evaluate the efficacy of extracorporeal shock wave lithotripsy (ESWL) for the management of refractory bile duct cholelithiasis in a third level referral centre...
  20. doi Natural history of small gallbladder polyps is benign: evidence from a clinical and pathogenetic study
    Antonio Colecchia
    Department of Internal Medicine and Gastroenterology, University of Bologna, Italy
    Am J Gastroenterol 104:624-9. 2009
    ..It is unclear if these polyps and gallstones represent different aspects of the same disease. The aim of this study was to characterize the natural history and pathogenesis of small gallbladder polyps...
  21. ncbi Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers
    G Mazzella
    Dipartimento di Malattie dell Apparato Digerente, del Metabolismo and delle Malattie Infettive, Azienda Ospedaliera di Bologna, Universita di Bologna, Italy
    Hepatology 33:504-8. 2001
    ..8 +/- 2.4 and 0.9 +/- 0.14 micromol/L, respectively. We conclude that increasing the dose of UDCA more effectively controls ICP and improves maternal clinical outcome after delivery...
  22. ncbi A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis
    F Azzaroli
    Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
    Aliment Pharmacol Ther 24:129-36. 2006
    ..Incidence of hepatocellular carcinoma in hepatitis C virus-related cirrhosis is 4% per year. Although cost-effective, current screening could be improved...
  23. ncbi Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis
    E Roda
    Department of Internal Medicine and Gastroenterology, University of Bologna, S Drsola Malpighi Hospital, Italy
    Dig Liver Dis 34:523-7. 2002
    ....
  24. ncbi The UDCA dosage deficit: a fate shared with CDCA
    Enrico Roda
    Dipartimento di Medicina Interna e Gastroenterologia, Universita di Bologna, Bologna, Italy
    Eur J Gastroenterol Hepatol 14:213-6. 2002
    ..It may be necessary to re-evaluate the dosage of UDCA that provides the most effective treatment...
  25. ncbi Transjugular intrahepatic portosystemic shunt: a case report of rescue management of unrestrainable variceal bleeding in a pregnant woman
    F Lodato
    Department of Digestive Diseases and Internal Medicine, S Orsola Malpighi Hospital, University of Bologna, Italy
    Dig Liver Dis 40:387-90. 2008
    ..Transjugular intrahepatic portosystemic shunt may represent a rescue treatment for failed attempts of band ligation or sclerotherapy...
  26. doi Generation of a novel antibody probe to the apical sodium-dependent bile acid transporter that inhibits ileal bile acid absorption
    M Montagnani
    Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
    Mol Pharm 6:1012-8. 2009
    ....
  27. ncbi Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study
    F Lodato
    Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
    J Viral Hepat 12:536-42. 2005
    ....
  28. ncbi Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy
    A Floreani
    Department of Surgical and Gastroenterological Sciences, Padua University, Padova, Italy
    Dig Liver Dis 40:366-70. 2008
    ..Intrahepatic cholestasis of pregnancy is a multifactorial disorder of pregnancy associated with a genetic background...
  29. ncbi Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations
    A Floreani
    Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy
    Aliment Pharmacol Ther 23:1649-53. 2006
    ..The aetiology of intrahepatic cholestasis of pregnancy is unknown, but more than 10 different MDR3 gene mutations have recently been identified...
  30. ncbi Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat
    J Lee
    Liver Center and Department of Medicine, Yale University School of Medicine, 1080 LMP, New Haven, CT 06520-8019, USA
    Gastroenterology 121:1473-84. 2001
    ..These responses may facilitate extrahepatic pathways for bile salt excretion during cholestasis...
  31. ncbi Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver
    C J Soroka
    Liver Center and Department of Medicine, Yale University School of Medicine, New Haven, CT 06520-8019, USA
    Hepatology 33:783-91. 2001
    ..This was in contrast to the progressive decrease in Mrp2 protein. Because Mrp3 is capable of transporting toxic bile acids, up-regulation of Mrp3 may compensate for the down-regulation of Mrp2 in obstructive cholestasis...
  32. ncbi Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients
    A Colecchia
    Dipartmento di Medicina Interna e Gastroenterologia Policlinico S Orsola Malpighi Via Massarenti 9, Bologna 40138, Italy
    World J Gastroenterol 12:5336-43. 2006
    ....